Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) — Cash Flow-to-Debt Ratio
Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) has a Cash Flow-to-Debt Ratio of 0.07x as of September 2025, meaning its operating cash flow of CN¥76.07 Million could theoretically repay 0% of its total liabilities (CN¥1.05 Billion) in one year. See 688621 financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Beijing Sun Novo Pharmaceutical Research Co Ltd Cash Flow-to-Debt Ratio (2017–2025)
Historical debt coverage capacity for Beijing Sun Novo Pharmaceutical Research Co Ltd across 9 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Beijing Sun Novo Pharmaceutical Research.
Annual Cash Flow-to-Debt Ratio for Beijing Sun Novo Pharmaceutical Research Co Ltd (2017–2025)
Year-by-year debt coverage analysis for Beijing Sun Novo Pharmaceutical Research Co Ltd. Check how high is Beijing Sun Novo Pharmaceutical Research's earnings quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.09x | CN¥93.21 Million | CN¥1.05 Billion | ▲ +145.0% |
| 2024 | 0.04x | CN¥32.02 Million | CN¥884.65 Million | ▼ -68.6% |
| 2023 | 0.12x | CN¥92.86 Million | CN¥805.76 Million | ▼ -38.5% |
| 2022 | 0.19x | CN¥103.96 Million | CN¥554.86 Million | ▲ +0.4% |
| 2021 | 0.19x | CN¥88.25 Million | CN¥473.01 Million | ▼ -43.2% |
| 2020 | 0.33x | CN¥62.99 Million | CN¥191.94 Million | ▼ -3.9% |
| 2019 | 0.34x | CN¥56.97 Million | CN¥166.76 Million | ▼ -1.1% |
| 2018 | 0.35x | CN¥44.11 Million | CN¥127.68 Million | ▲ +231.3% |
| 2017 | 0.10x | CN¥8.01 Million | CN¥76.82 Million | — |